Starting November 1, 2020, the Lyme Total Antibody test will temporarily not be performed in-house and will be sent out to the Mayo Clinic Laboratories using the Lyme Disease Serology, Serum. This is due to the backorder of reagents from the vendor until approximately January 2021.
Lyme Disease Serology, Serum is available to order in Epic. Lyme Total Antibody will still be available to order, however, when the specimen arrives to the laboratory the order will be switched to the Lyme Disease Serology, Serum.
Similarly, to the current in-house test, the Mayo assay is also a Lyme total antibody assay, detecting both IgG and IgM antibodies, with the same specimen type as the in-house test. However, test turn-around-times may be increased.
Lastly, this change will have no effect on the reflexing of positive samples to the confirmatory Lyme Disease Antibody, Immunoblot, Serum.
Effective September 28th, 2020, a new generation of the serum kappa/lambda free light chain assay has been implemented.
With the implementation of the new generation of the assay there is an approximately 20% negative bias for kappa free light chains in serum containing >20 mg/dL kappa free light chain. This may affect the trending for patient who are serially monitored by this assay.
As of August 26, 2020, the following tests will be obsoleted or made as lab orderables only. This was implemented to streamline protein electrophoresis orders and ensure that patients receive the recommended testing for the assessment of plasma cell proliferative diseases.
In addition to streamlining protein electrophoresis orders, order questions have been implemented to the available tests to access the reason for ordering to ensure that the proper reflex testing is applied.
For more information, see the lab test directory under the available tests for a protein electrophoresis orders tip sheet entitled “Orders- Protein Orderable Changes”
Effective April 22nd, 2020, the following ANA (Antinuclear Antibodies) Tests’ name will be updated. The change in naming convention comes in hopes of enhancing proper test utilization. This update includes only the name change with no changes in laboratory testing workflow.
As of February 12, 2020 testing for fecal calprotectin will be brought in-house.
As result Calprotectin, Feces (LAB3290) will be replaced with Calprotectin, Feces (LAB1230580).
Please note the following differences between the new and previous test in terms of specimen requirements and reference ranges.
Questions may be directed to the Toxicology Laboratory using the “Contact Us” link above.
As of January 8th 2020 the peanut component rAra h 6 will be added to the following testing panels.
IgE Peanuts, Component Allergen Panel (LAB3424)
IgE Peanut, Component Allergen Panel if Positive (LAB3423)
Effective December 11th, 2019, Spectrum Health Regional Laboratory’s Immunochemistry laboratory will be upgrading the following tests from the Immunoassay Vidas platform to the Multiplex flow immunoassay Bioplex 2200 platform.
Cytomegalovirus IgG Antibody
Cytomegalovirus IgM Antibody
Toxoplasma IgG Antibody
Toxoplasma IgM Antibody
Lyme Total Antibody
All tests will continue to have the same collection instructions, processing instructions, rejection criteria, specimen stability, turn-around-time, and qualitative reference ranges of negative.
As of November 25th 2019 the following tests for Herpes Simplex Virus (HSV) IgM antibody testing will be obsoleted.
Herpes IgM Antibody Screen – LAB3576
Herpes Simplex Virus (HSV) Antibody Screen, IgM, by EIA, Serum – LAB3578
Herpes Simplex Panel – LAB1230539